Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Integra Therapeutics
Deal Size : $42.0 million
Deal Type : Licensing Agreement
Caszyme And Integra Ink Deal for Novel CRISPR Cas12l Nucleases
Details : The agreement aims for the use of Caszyme's novel Cas12l nucleases to develop safer and more efficient gene and cell therapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 11, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Integra Therapeutics
Deal Size : $42.0 million
Deal Type : Licensing Agreement
Reset All
